Marshall Wace LLP Purchases Shares of 18,102 HUTCHMED (China) Limited (NASDAQ:HCM)

Marshall Wace LLP acquired a new position in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 18,102 shares of the company's stock, valued at approximately $261,000.

Several other institutional investors have also recently made changes to their positions in the stock. Crossmark Global Holdings Inc. lifted its holdings in HUTCHMED by 10.7% in the 4th quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company's stock worth $268,000 after purchasing an additional 1,799 shares in the last quarter. Blue Trust Inc. raised its stake in shares of HUTCHMED by 99.9% during the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company's stock valued at $102,000 after acquiring an additional 3,532 shares in the last quarter. XY Capital Ltd bought a new stake in HUTCHMED during the 4th quarter valued at $673,000. Summit Trail Advisors LLC increased its stake in shares of HUTCHMED by 14.4% during the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock valued at $189,000 after buying an additional 1,647 shares during the period. Finally, ABC Arbitrage SA bought a new stake in shares of HUTCHMED in the fourth quarter valued at about $500,000. Institutional investors and hedge funds own 8.82% of the company's stock.

Analyst Ratings Changes

Separately, StockNews.com raised shares of HUTCHMED from a "hold" rating to a "buy" rating in a research report on Friday, March 21st.

HUTCHMED Stock Performance

Shares of NASDAQ:HCM traded down $0.06 during midday trading on Thursday, hitting $14.54. 49,162 shares of the stock were exchanged, compared to its average volume of 104,401. The company has a 50 day moving average price of $14.80 and a 200-day moving average price of $15.54. HUTCHMED has a twelve month low of $11.51 and a twelve month high of $21.92. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.